2020
Primary dural lymphomas: Clinical presentation, management, and outcome
Karschnia P, Batchelor TT, Jordan JT, Shaw B, Winter SF, Barbiero FJ, Kaulen LD, Thon N, Tonn J, Huttner AJ, Fulbright RK, Loeffler J, Dietrich J, Baehring JM. Primary dural lymphomas: Clinical presentation, management, and outcome. Cancer 2020, 126: 2811-2820. PMID: 32176324, DOI: 10.1002/cncr.32834.Peer-Reviewed Original ResearchConceptsPrimary dural lymphomaPrimary CNS lymphomaNon-Hodgkin lymphomaCNS lymphomaOverall survivalDural lymphomaPrimary central nervous system lymphomaT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaCentral nervous system lymphomaLarge B-cell lymphomaMedian apparent diffusion coefficient (ADC) valuesAvid contrast enhancementMedian overall survivalCerebrospinal fluid analysisNervous system lymphomaMarginal zone lymphomaB-cell lymphomaExtra-axial massApparent diffusion coefficient (ADC) valuesMassachusetts General HospitalAggressive surgeryMultimodality treatmentSystem lymphomaSystemic involvement
2013
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ, Piepmeier JM, Saltzman WM. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 11751-11756. PMID: 23818631, PMCID: PMC3718184, DOI: 10.1073/pnas.1304504110.Peer-Reviewed Original Research
2010
Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1
Huttner AJ, Kieran MW, Yao X, Cruz L, Ladner J, Quayle K, Goumnerova LC, Irons MB, Ullrich NJ. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatric Blood & Cancer 2010, 54: 890-896. PMID: 20310005, DOI: 10.1002/pbc.22462.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsChildChild, PreschoolDNA Modification MethylasesDNA Repair EnzymesErbB ReceptorsGene DosageGlioblastomaHumansImmunohistochemistryIn Situ HybridizationInfantKaplan-Meier EstimateMaleNeurofibromatosis 1PTEN PhosphohydrolaseRetrospective StudiesTumor Suppressor Protein p53Tumor Suppressor ProteinsConceptsNeurofibromatosis type 1Malignant tumorsType 1Median overall survivalLow-grade tumorsPeripheral nervous systemEpidermal growth factor receptor copy numberNon-NF1 patientsAdditional molecular studiesClinicopathologic studyOverall prognosisOverall survivalRetrospective reviewVascular proliferationPathologic indicatorsPatientsNervous systemTumors differsSame time periodGlioblastomaSmall sample sizeTumorsMethylguanine-DNA methyltransferase (MGMT) geneSurvivalChildren